CRNX News and Press, Crinetics Pharmaceuticals Inc. From 03/22/21

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today provid...

- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease Selected for Oral and Late-breaking Presentations - SAN DIEGO, March 12...

SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announc...

SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...

The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with this event. For further details see: Crinetics Pharmaceuticals (CRNX) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - - Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing’s disease expected in January 2021 - - Initiation of Pha...

Gainers: [[ISR]] +67.9%. [[CRNX]] +7.9%. [[SCPE]] +6.3%. [[SCYX]] +6.1%. [[ENSV]] +5.3%.Losers: [[MXC]] -11.5%. [[CLSD]] -10.0%. [[DWSN]] -9.9%. [[IRIX]] -8.9%. [[TITN]] -6.6%. For further details see: ISR, CRNX, MXC and CLSD among after-hours movers

Gainers: [[OBLN]] +81%. [[MRIN]] +9.8%. [[FATE]] +8.8%. [[CRNX]] +6.7%. [[PROG]] +6.1%.Losers: [[HX]] -6.2%. [[INN]] -6.2%. [[RIDE]] -5.6%. [[MBIO]] -4.4%. [[EVK]] -3.8%. For further details see: RIDE, FATE, MBIO and MRIN among after-hours movers

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below: About Crinetics Pharmaceuticals ...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announce...